Assignee
MOLECULAR PARTNERS AG
CH·19 granted patents·23 pending applications·92 citations·filing 2013–2025
Top patents by PatentIndex Score
42 records- 0195US10646542B2Modified binding proteins inhibiting the VEGF-A receptor interactionMOLECULAR PARTNERS AG·Filed 2017·Granted May 12, 2020·6 cites·19 claims
- 0295US9458211B1Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domainsMOLECULAR PARTNERS AG·Filed 2016·Granted Oct 4, 2016·43 cites·27 claims
- 0392US11578427B2Designed ankyrin repeat domains with altered surface residuesMOLECULAR PARTNERS AG·Filed 2021·Granted Feb 14, 2023·4 cites·21 claims
- 0489US11466062B2Ankyrin repeat binding proteins and their usesMOLECULAR PARTNERS AG·Filed 2021·Granted Oct 11, 2022·4 cites·21 claims
- 0585US9849158B2Modified binding proteins inhibiting the VEGF-A receptor interactionMOLECULAR PARTNERS AG·Filed 2016·Granted Dec 26, 2017·3 cites·19 claims
- 0685US9775912B2Designed repeat proteins binding to serum albuminMOLECULAR PARTNERS AG·Filed 2016·Granted Oct 3, 2017·5 cites·21 claims
- 0785US9289466B2Modified binding proteins inhibiting the VEGF-A receptor interactionMOLECULAR PARTNERS AG·Filed 2014·Granted Mar 22, 2016·5 cites·23 claims
- 0885US9163070B2Designed ankyrin repeat proteins binding to platelet-derived growth factorMOLECULAR PARTNERS AG·Filed 2013·Granted Oct 20, 2015·7 cites·27 claims
- 0984US10717772B2Recombinant binding proteins targeting HER2 and serum albumin, and their usesMOLECULAR PARTNERS AG·Filed 2017·Granted Jul 21, 2020·5 cites·20 claims
- 1081US11834504B2DARPin based multi-specific t-cell engagersMOLECULAR PARTNERS AG·Filed 2022·Granted Dec 5, 2023·1 cites·21 claims
- 1179US12435445B2Designed ankyrin repeat domains with altered surface residuesMOLECULAR PARTNERS AG·Filed 2023·Granted Oct 7, 2025·0 cites·1 claims
- 1278US10370414B2Binding proteins comprising at least two repeat domains against HER2MOLECULAR PARTNERS AG·Filed 2013·Granted Aug 6, 2019·6 cites·23 claims
- 1375US9717802B2Capping modules for designed ankyrin repeat proteinsMOLECULAR PARTNERS AG·Filed 2015·Granted Aug 1, 2017·1 cites·22 claims
- 1474US2023243070A1Recombinant peptide-mhc complex binding proteins and their generation and useMOLECULAR PARTNERS AG·Filed 2023·Application pending·0 cites
- 1570US2021069293A1Modified binding proteins inhibiting the vegf-a receptor interactionMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 1667US11453708B2Designed ankyrin repeat proteins binding to hepatocyte growth factorMOLECULAR PARTNERS AG·Filed 2014·Granted Sep 27, 2022·2 cites·22 claims
- 1766US2022106707A1Recombinant peptide-mhc complex binding proteins and their generation and useMOLECULAR PARTNERS AG·Filed 2021·Application pending·0 cites
- 1865US11332501B2Recombinant binding proteins and their useMOLECULAR PARTNERS AG·Filed 2018·Granted May 17, 2022·0 cites·20 claims
- 1964US10322190B2Capping modules for designed ankyrin repeat proteinsMOLECULAR PARTNERS AG·Filed 2017·Granted Jun 18, 2019·0 cites·21 claims
- 2064US2024254229A1NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERSMOLECULAR PARTNERS AG·Filed 2023·Application pending·0 cites
- 2161US2024190999A1Multispecific proteinsMOLECULAR PARTNERS AG·Filed 2023·Application pending·0 cites
- 2259US2022235103A1Novel ankyrin repeat binding proteins and their usesMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 2359US2025042957A1Designed repeat domains with dual binding specificity and their useMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 2456US2024228545A9Charge modified designed repeat domains and their useMOLECULAR PARTNERS AG·Filed 2023·Application pending·0 cites
- 2554US2015344539A1Binding proteins inhibiting the vegf-a receptor interactionMOLECULAR PARTNERS AG·Filed 2014·Application pending·0 cites
- 2653US10155791B2Recombinant binding proteins and their useMOLECULAR PARTNERS AG·Filed 2016·Granted Dec 18, 2018·0 cites·23 claims
- 2753US2021130420A1Recombinant binding proteins targeting her2 and serum albumin, and their usesMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 2850US2024156980A1Protease cleavable prodrugsMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 2949US12331090B2Multispecific proteinsMOLECULAR PARTNERS AG·Filed 2021·Granted Jun 17, 2025·0 cites·19 claims
- 3048US12441772B2Designed ankyrin repeat domain with improved stabilityMOLECULAR PARTNERS AG·Filed 2020·Granted Oct 14, 2025·0 cites·17 claims
- 3148US2024108746A1Novel slow-release prodrugsMOLECULAR PARTNERS AG·Filed 2021·Application pending·0 cites
- 3248US2023041822A1Recombinant peptide-mhc complex binding proteins and their generation and useMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 3347US2020385488A1Multispecific proteinsMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 3447US2024052033A1Recombinant cd3 binding proteins and their useMOLECULAR PARTNERS AG·Filed 2021·Application pending·0 cites
- 3547US2025074994A1Novel darpin based cd70 engagersMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 3646US2024317852A1Novel darpin based cd33 engagersMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 3746US2024150475A1Novel darpin based cd123 engagersMOLECULAR PARTNERS AG·Filed 2022·Application pending·0 cites
- 3843US2022298212A1Recombinant 4-1bb binding proteins and their useMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 3943US2015368302A1Designed ankyrin repeat proteins binding to platelet-derived growth factorMOLECULAR PARTNERS AG·Filed 2015·Application pending·0 cites
- 4042US2022242973A1Recombinant fap binding proteins and their useMOLECULAR PARTNERS AG·Filed 2020·Application pending·0 cites
- 4142US2024279309A1Recombinant cd40 binding proteins and their useMOLECULAR PARTNERS AG·Filed 2021·Application pending·0 cites
- 4237US2025332297A1Dll3-specific binding constructs and their use in radiotherapyMOLECULAR PARTNERS AG·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MOLECULAR PARTNERS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →